Skip to main content

Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023

HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 500542. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 47846, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.




View source version on accesswire.com:
https://www.accesswire.com/743362/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Wednesday-March-15-2023

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.80
-2.84 (-1.35%)
AAPL  272.93
-1.30 (-0.47%)
AMD  202.94
-7.92 (-3.75%)
BAC  52.32
+0.63 (1.22%)
GOOG  307.17
-5.86 (-1.87%)
META  656.39
+2.70 (0.41%)
MSFT  401.54
+0.94 (0.23%)
NVDA  185.18
-10.38 (-5.31%)
ORCL  149.35
+1.46 (0.99%)
TSLA  407.89
-9.51 (-2.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.